That a humoral factor was the causative agent in idiopathic thrombocytopenic purpura was suggested nearly 30 years ago after the observation that mothers with the disease often give birth to children who develop transient thrombocytopenia.1 Maternal platelet autoantibodies were presumed to pass into the fetal circulation. With present techniques2 3 platelet autoantibodies are detectable in most patients with idiopathic thrombocytopenic purpura. We have therefore tried to confirm the passage of autoantibodies through the placental barrier and determine their immunochemical characteristics. We used specific antiglobulin reagents labelled with fluorescein isothiocyanate.
Patients and methods
We studied four pregnant women who fulfilled the criteria for idiopathic thrombocytopenic purpura.3 Three were primigravidae whose thrombocytopenia was first diagnosed during pregnancy. Two had platelet counts below 40 x 109/1 (40 000/mm3) on the day of diagnosis and were treated with prednisone two and three weeks, respectively, before delivery. The 
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In all four cases we confirmed the suspected transfer of IgG autoantibodies through the placenta. We also showed in two cases that additional IgM antibodies did not pass the placental barrier. The gradual disappearance of antibodies from the infants' platelets supports the passively acquired nature of these antibodies. This is further supported by the finding that the IgG subclass and blood group specificity pattern of the autoantibodies in two cases were identical in the mother and newborn.
None of the newborns developed severe thrombocytopenia, and no relation was found between the degree of platelet sensitisation in mother and child and the platelet count in the neonatal periods. Mothers, in remission of idiopathic thrombocytopenic purpura after splenectomy,l or with autoantibodies and moderate thrombocytopenia (80-180 x 109 platelets/l), however, may give birth to a severely thrombocytopenic infants. Alloantibodies against platelets may also be formed by the woman during pregnancy, usually resulting in a more severe transient neonatal thrombocytopenia but with completely different therapeutic consequences.4 The introduction of reliable tests for detecting antibodies against platelets makes it possible to determine the presence of these antibodies and to differentiate between their autoimmune and alloimmune character.4 5 This enables optimal measures and precautions to be taken in the present or future pregnancy, delivery, and neonatal period. 
